Käsmann Lukas, Degerli Esra, El-Marouk Karim, Manapov Farkhad
Department of Radiation Oncology, University Hospital, Ludwig-Maximilians-University (LMU) Munich, Munich, Germany.
German Center for Lung Research (DZL), Partner Site Munich, Munich, Germany.
Front Oncol. 2024 Mar 19;14:1226422. doi: 10.3389/fonc.2024.1226422. eCollection 2024.
Durvalumab after chemotherapy in non-operable stage III non-small cell lung cancer (NSCLC) is the standard of care worldwide. We present a patient with the incidental discovery of a unilateral MALT lymphoma of the adrenal gland and adrenalitis during durvalumab maintenance treatment detected by 18F-FDG-PET/CT. We assessed the clinical and histopathological findings, radiological examinations and overall treatment. Our work emphasizes the significance of considering other differential diagnoses and the importance of multidisciplinary treatment of the findings, especially within clinical trials.
在不可切除的 III 期非小细胞肺癌(NSCLC)中,化疗后使用度伐鲁单抗是全球的治疗标准。我们报告了 1 例在度伐鲁单抗维持治疗期间经 18F-FDG-PET/CT 偶然发现肾上腺单侧黏膜相关淋巴组织淋巴瘤和肾上腺炎的患者。我们评估了临床和组织病理学检查结果、影像学检查及整体治疗情况。我们的工作强调了考虑其他鉴别诊断的重要性以及对这些检查结果进行多学科治疗的重要性,尤其是在临床试验中。